MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
BLCO stock logo

BLCO

Bausch + Lomb Corporation

$14.94
0.45
 (3.07%)
Exchange:   NYSE
Market Cap:   5.287B
Shares Outstanding:   350M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  Brenton L. Saunders
Full Time Employees:  13500
Address: 
520 Applewood Crescent
Vaughan
ON
L4K 4B4
CA
Website:  https://www.bausch.com
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

EPS

🔒 You are currently logged out

Login
View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Current Key Metrics

🔒 You are currently logged out

Login

Forward P/E Ratios

🔒 You are currently logged out

Login

SWOT Analysis

🔒 You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

🔒 Premium Feature

Log in to access the BLCO Intrinsic Value Calculator

🔑 Log In
📝 Sign Up Free

Get comprehensive stock analysis with premium features

🔒 You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

18-08-2025 17:01
Bausch + Lomb Announces Board Changes